(於開曼群島註冊成立之有限公司) (股份代號: 8622) 董事名單及其角色及職能 華康生物醫學控股有限公司之董事會（「董事會」）成員如下載列： 執行董事 HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED 華康生物醫學控股有限公司 M ： 相關董事委員會成員 董事會已成立三個委員會，而該等委員會的成員如下載列： | | 董事委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 董事 | | | | | | 張玉靜女士 | | – | – | C | | 張春光先生 | | – | M | – | | 周國輝博士 | | M | M | M | | 王亞純女士 | | M | C | M | | 徐永得先生 | | C | – | M | 非執行董事 卜素博士 徐明博士 香港，二零二五年八月二十九日 獨立非執行董事 周國輝博士 王亞純女士 徐永得先生 附註： C ： 相關董事委員會主席 張玉靜女士（主席） 張春光先生 潘禮賢先生（合規主任） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 華康生物醫學控股有限公司（「本公司」），連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」））謹此宣佈張曙光先生（「張先生」）經與董事會討論後，其為投放 更多時間專注於本公司之附屬公司的業務管理而非本公司的執行職能，故已辭任本公司執行 董事（「執行董事」）；董事會主席（「董事會主席」）；提名委員會（「提名委員會」）主 席及根據香港聯合交易所有限公司（「聯交所」）GEM 證券上市規則（「GEM 上市規則」） 第 5.24 條的授權代表（「授權代表」），自二零二五年八月二十九日起生效。 張先生已經確認，彼等與董事會概無意見分歧，亦無任何與其辭任有關之其他事宜須提請本 公司股東或聯交所注意。 HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED 華康生物醫學控股有限公司 (於開曼群島註冊成立之有限公司) (股份代號: 8622) (1)執行董事之辭任；(2)變更主席 ...

Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限公司 (incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限公司) Stock Code 股份代號 : 8622 2025 INTERIM REPORT 中期報告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors sho ...

Group 1 - The core viewpoint of the article highlights Huakang Biomedical's financial performance for the six months ending June 30, 2025, showing a revenue of 12.329 million RMB, which represents a year-on-year increase of 3.4% [1] - The company reported a net loss of 2.369 million RMB, which is an increase of 33.2% compared to the previous year [1] - The basic loss per share is reported at 0.47 cents [1] Group 2 - The increase in revenue is attributed to higher sales of male infertility in vitro diagnostic reagents and a series of parasitic testing reagents during the reporting period [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED 華康生物醫學控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：8622） 截至二零二五年六月三十日止六個月的 中期業績公告 華 康 生 物 醫 學 控 股 有 限 公 司（「本公司」，及 其 附 屬 公 司，「本集團」）董 事（「董 事」）會 （「董事會」）欣 然 宣 佈 本 集 團 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 的 未 經 審 核 簡 明 綜 合 財 務 業 績（「二零二五年中期報告」）連 同 二 零 二 四 年 同 期 未 經 審 核 比 較 數 字。本 公 告 載 列 本 集 團 二 零 二 五 年 中 期 報 告 全 文，並 遵 守 香 港 聯 合 ...

華康生物醫學控股有限公司 (於開曼群島註冊成立之有限公司) (股份代號: 8622) 董事會會議通告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 華康生物醫學控股有限公司 (「本公司」) 之董事 (「董事」) 會 (「董事會」) 謹此宣佈，本 公司董事會會議將於二零二五年八月十五日 (星期五) 舉行，藉此 (其中包括) 審議及批准本 公司及其附屬公司於截至二零二五年六月三十日止六個月之未經審核簡明綜合中期業績及其 公佈，以及考慮派發中期股息（如有）及處理任何其他事項。 HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED 香港，二零二五年八月五日 於本公告日期，執行董事為張曙光先生、張春光先生、潘禮賢先生及張玉靜女士；非執行董 事為卜素博士及徐明博士；及獨立非執行董事為周國輝博士、王亞純女士及徐永得先生。 本公告的資料乃遵照《香港聯合交易所有限公司的 GEM 證券上市規則》而刊載，旨在提供 有 關本公司的資料；董事 ...

Group 1 - The Hong Kong biotechnology stocks collectively rose, with notable increases in several companies' stock prices [1][2] - Beihai Kangcheng-B saw a rise of nearly 19%, while other companies like Gilead Sciences-B and Ascentage Pharma-B also experienced significant gains of over 15% and 9% respectively [1][2] - The overall trend indicates a positive sentiment in the biotechnology sector, with multiple companies achieving gains of over 5% [1][2] Group 2 - Specific stock performance includes: Beihai Kangcheng-B at 18.99% increase, Gilead Sciences-B at 15.30%, and Ascentage Pharma-B at 9.48% [2] - The market capitalization of these companies varies significantly, with Gilead Sciences-B at approximately 11.477 billion and Ascentage Pharma-B at about 29.86 billion [2] - Other notable performers include Jiahua Bio-B and Beikang Medical-B, both showing increases of over 7% [1][2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華康生物醫學控股有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08622 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | 本月底法 ...

Company Overview - Huakang Biomedical Holdings Limited has established itself as an expert in male infertility diagnostics after over a decade of research in the assisted reproductive technology market [2] - The company has a professional research team and solid partnerships with hospitals and medical institutions, producing in vitro diagnostic reagents for male infertility, parasite detection, and EB virus testing [2] - Huakang Biomedical is one of the top three manufacturers in China's male infertility in vitro diagnostic reagent market [2] Financial Performance - As of December 31, 2024, Huakang Biomedical reported total revenue of 25.359 million yuan, a year-on-year increase of 2.96% [1] - The company recorded a net profit attributable to shareholders of -4.158 million yuan, with a year-on-year growth of 28.09% [1] - The gross profit margin stands at 67.32%, and the debt-to-asset ratio is 17.13% [1] Market Position and Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 5.28 times, with a median of 4.58 times [1] - Huakang Biomedical's P/E ratio is -39.57 times, ranking 88th in the industry [1] - Other companies in the sector have P/E ratios such as: Qingdao Haier Biomedical (0.71), Kingsray Biotechnology (1.05), Baixin International (1.21), Dongrui Pharmaceutical (2.86), and Charoen Pokphand International (4.14) [1] Future Outlook - The company plans to continue investing in research and development of fertility products and introduce high-level international assisted reproductive technologies to China [2] - Huakang Biomedical aims to expand its business along the assisted reproductive technology industry chain, leveraging its strong research capabilities to create value for society [2]

Market Trends and Demand - In 2024, the national birth rate in the PRC recorded a modest rebound to 6.77‰, compared to 6.39‰ in 2023, marking the first increase after seven consecutive years of decline[15]. - The new fertility support policy issued by the PRC in October 2024 is expected to drive market demand growth for the Group's biological reagents and auxiliary reproductive supplies and equipment[36]. - The Group's focus on male infertility diagnosis positions it to benefit from the market demand growth driven by the new fertility support policy[36]. - Sales of biological reagents and auxiliary reproductive supplies and equipment remained stable, driven by sustained demand in fertility-related healthcare services[16]. - The sales of parasite antibody detection reagents rose to RMB3.8 million, reflecting sustained market demand[26]. Financial Performance - The Group's revenue increased by approximately RMB730,000, or approximately 3.0%, from approximately RMB24.6 million for the year ended 31 December 2023 to approximately RMB25.4 million for the year ended 31 December 2024[39]. - Revenue from the biological reagents and auxiliary reproductive supplies and equipment segment reached RMB25.4 million, a 4.3% increase compared to 2023, with core male fertility IVD reagents sales growing by 1.7% year-on-year to RMB19.4 million, accounting for 76.4% of the segment's total revenue[26]. - Gross profit increased to approximately RMB17.1 million for the year ended 31 December 2024, representing an increase of approximately RMB979,000 or 6.1% from approximately RMB16.1 million in 2023, with gross profit margin rising from 65.3% to 67.3%[42][44]. - The loss attributable to owners of the Company was approximately RMB4.2 million for the year ended 31 December 2024, a decrease of approximately RMB1.6 million or 28.1% from RMB5.8 million in 2023[60][64]. - Basic loss per share improved to RMB0.86 cents for the year ended 31 December 2024, compared to RMB1.39 cents in 2023[61][65]. Strategic Decisions and Developments - The Group terminated the Anoectochilus Formosanus Extractive project in late 2023, ensuring minimal financial impact through a repayment agreement signed in March 2024[17]. - The healthcare products and supplements segment temporarily suspended sales in 2024 following a strategic decision due to prolonged market headwinds[16]. - The Group strategically decided to temporarily suspend sales of the "Nutronic" brand in 2024 due to prolonged market challenges, while retaining valuable resources for future synergies[30]. - In January 2025, the Group signed a non-binding Memorandum of Understanding with Hunan Keyue Biotechnology Company Limited, proposing the acquisition of its equity to synergize resources in the growing women's health market[17]. - The Group intends to acquire equity interest in Keyue Bio to integrate resources and expand the female health market, leveraging its established overseas supply chains and international sales networks[31]. Research and Development - Research and development expenses increased to approximately RMB2.8 million for the year ended 31 December 2024, an increase of approximately RMB272,000 or 10.7% from RMB2.6 million in 2023, driven by costs associated with product improvements and new product development[53][57]. - The Group completed Class II medical device registration of semen biochemical immunoassay equipment in late 2024, enhancing its reagent diagnostic capabilities[27]. - The Group plans to deepen technological research and development, expand its distribution network, and explore emerging markets such as Southeast Asia to drive growth through innovation[37]. Corporate Governance and Management - The company has adopted and complied with the Corporate Governance Code during the year ended December 31, 2024[176]. - The board is committed to high corporate governance standards to safeguard shareholder interests and enhance corporate value[175]. - The Company emphasizes transparency and accountability in its business strategies and policies[175]. - The roles of chairman and chief executive officer are held by Mr. Zhang Shuguang and Mr. Zhang Chunguang respectively, ensuring a balance of power and authority[200]. - The Company has established board committees with specific written terms of reference to clearly define their authority and duties[188]. Shareholder and Financial Management - The Company successfully placed 20,000,000 new ordinary shares on January 31, 2024, raising net proceeds of approximately RMB 1.82 million, which has been fully utilized[93]. - A second placement of 31,000,000 new ordinary shares on March 21, 2024, raised net proceeds of approximately RMB 2.94 million, also fully utilized by December 31, 2024[94]. - A third placement of 31,000,000 new ordinary shares on April 23, 2024, raised net proceeds of approximately RMB 2.74 million, fully utilized by December 31, 2024[95]. - As of December 31, 2024, the total cash and bank balances were approximately RMB 36.5 million, an increase from RMB 32.9 million as of December 31, 2023, primarily due to loan receivable repayments[69]. - The gearing ratio as of December 31, 2024, was approximately 2.2%, down from approximately 4.5% in 2023, indicating improved financial stability[70].